Profound Medical Corp. (PROF) intrinsic value & 10-year financials
Profound Medical Corp. (PROF) has a Graham intrinsic value of $46.83 per share. At $6.01 on Oct 17, 2026, the stock trades 87% below that value. Over the last 4 fiscal years revenue grew 65.2% a year to $16.1M, with an average return on invested capital of -296.8%.
- Graham intrinsic value
- $46.83
- Share price (Oct 17, 2026)
- $6.01
- Price vs Graham value
- 87% below
- Market cap
- $181.7M
- Revenue (FY2025)
- $16.1M
- Revenue growth (4-yr CAGR)
- 65.2%
- ROIC (10-yr avg)
- -296.8%
- Free cash flow (FY2025)
- -$38.4M
PROF 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $16.1M | -$42.6M | $1.41 | -$38.4M | -256.3% | -382.3% |
| FY2024 | $9.7M | -$27.8M | $1.12 | — | -339.4% | -287.6% |
| FY2023 | $5.9M | -$28.3M | $1.34 | — | -485.7% | -220.5% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Profound Medical Corp. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Profound Medical Corp. has historically struggled to out-earn its cost of capital, averaging just -3.0% ROIC.
Profound Medical Corp. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Profound Medical Corp. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $46.83 per share.